Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

329600

Sigma-Aldrich

Erastin

≥98% (HPLC), solid, antitumor agent, Calbiochem®

Synonyme(s) :

Erastin, 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)-piperazin-1-yl)-ethyl)-3-(2-ethoxyphenyl)-3H-quinazolin-4-one

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C30H31ClN4O4
Numéro CAS:
571203-78-6
Poids moléculaire :
547.04
Numéro MDL:
MFCD09837984
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

product name

Erastin, A cell-permeable piperazinyl-quinazolinone compound that exhibits oncogene-selective lethality.

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

solid

Fabricant/nom de marque

Calbiochem®

Conditions de stockage

OK to freeze
protect from light

Couleur

white

Solubilité

DMSO: 50 mg/mL

Conditions d'expédition

wet ice

Température de stockage

−20°C

InChI

1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3

Clé InChI

BKQFRNYHFIQEKN-UHFFFAOYSA-N

Description générale

A cell-permeable piperazinyl-quinazolinone compound that exhibits oncogene-selective lethality. Shown to bind mitochondrial voltage-dependent anion channels (VDAC) and alter its gating; rapidly induce an oxidative, non-apoptotic cell death in several human tumors harboring activating mutations in the RAS-RAF-MEK signaling (EC50 = 6.0 µM in BJ-TERT/LT/ST/RASV12 cells).

Conditionnement

Packaged under inert gas

Avertissement

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Autres remarques

Yagoda, N., et al. 2007. Nature447, 864.

Informations légales

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 4

1 of 4

Ammonium iron(III) citrate reagent grade, powder

Sigma-Aldrich

F5879

Ammonium iron(III) citrate

Nucléase Benzonase® ≥250 units/μL, ≥90% (SDS-PAGE), recombinant, expressed in E. coli, buffered aqueous glycerol solution

Millipore

E1014

Nucléase Benzonase®

Hémine BioXtra, from Porcine, ≥96.0% (HPLC)

Sigma-Aldrich

51280

Hémine

N-Acetyl-L-cysteine Sigma Grade, ≥99% (TLC), powder

Sigma-Aldrich

A7250

N-Acetyl-L-cysteine

DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition.
Eikan Mishima et al.
Nature, 619(7968), E9-E18 (2023-07-06)
Zhenyi Su et al.
Nature cancer, 4(4), 564-581 (2023-03-28)
Although the gain of function (GOF) of p53 mutants is well recognized, it remains unclear whether different p53 mutants share the same cofactors to induce GOFs. In a proteomic screen, we identified BACH1 as a cellular factor that recognizes the
Jiashuo Zheng et al.
Cell death & disease, 12(7), 698-698 (2021-07-15)
Sorafenib, a protein kinase inhibitor approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma, has been repeatedly reported to induce ferroptosis by possibly involving inhibition of the cystine/glutamate antiporter, known as system xc-. Using a combination of
Zhuhui Yuan et al.
Oxidative medicine and cellular longevity, 2022, 3403009-3403009 (2022-10-21)
Ionizing radiation-derived oxidative stress and ferroptosis are one of the most important biological effects on destroying the liver tumor, whereas radioresistance of liver tumor remains a leading cause of radiotherapy (RT) failure mainly because of the protective antiferroptosis, in which
Natalie K Horvat et al.
ACS nano, 18(17), 11025-11041 (2024-04-17)
ALK-positive NSCLC patients demonstrate initial responses to ALK tyrosine kinase inhibitor (TKI) treatments, but eventually develop resistance, causing rapid tumor relapse and poor survival rates. Growing evidence suggests that the combination of drug and immune therapies greatly improves patient survival;
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique